Advertisement

Topics

Diclofenac Sodium Ophthalmic Solution, 0.1% (Sterile) | Diclofenac Sodium [Rebel Distributors Corp] | BioPortfolio

12:08 EST 27th January 2019 | BioPortfolio

Note: While we endeavour to keep our records up-to-date one should not rely on these details being accurate without first consulting a professional. Click here to read our full medical disclaimer.

Diclofenac Sodium Ophthalmic Solution 0.1% is a sterile, topical, non-steroidal, anti-inflammatory product for ophthalmic use. Diclofenac Sodium is designated chemically as 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt, with an empirical formula of CHCINO Na. The structural formula of diclofenac sodium is:

Diclofenac Sodium Ophthalmic is available as a sterile solution, which contains diclofenac sodium 0.1% (1 mg/mL).

Inactive Ingredients: polyoxyl 35 castor oil, Boric acid, tromethamine, sorbic acid (2 mg/mL), edetate disodium (1 mg/mL), and purified water.

Diclofenac Sodium is a faintly yellow-white to light-beige, slightly hygroscopic crystalline powder. It is freely soluble in methanol, sparingly soluble in water, very slightly soluble in acetonitrile, and insoluble in chloroform and in 0.1N hydrochloric acid. Its molecular weight is 318.14. Diclofenac Sodium Ophthalmic 0.1% is an iso-osmotic solution with an osmolality of about 300 mOsmol/1000 g, buffered at approximately pH 7.2. Diclofenac Sodium Ophthalmic solution has a faint characteristic odor of castor oil.

Diclofenac Sodium is one of a series of phenylacetic acids that has demonstrated anti-inflammatory and analgesic properties in pharmacological studies. It is thought to inhibit the enzyme cyclooxygenase, which is essential in the biosynthesis of prostaglandins.

Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.

Results from a bioavailability study established that plasma levels of diclofenac following ocular instillation of two drops of Diclofenac Sodium Ophthalmic to each eye were below the limit of quantification (10 ng/mL) over a 4-hour period.

This study suggests that limited, if any, systemic absorption occurs with Diclofenac Sodium Ophthalmic.

Postoperative Anti-Inflammatory Effects:

In two double-masked, controlled, efficacy studies of postoperative inflammation, a total of 206 cataract patients were treated with Diclofenac Sodium Ophthalmic and 103 patients were treated with vehicle placebo. Diclofenac Sodium Ophthalmic was favored over vehicle placebo over a 2-week period for the clinical assessments of inflammation as measured by anterior chamber cells and flare.

In double-masked, controlled studies of corneal refractive surgery (radial keratotomy (RK) and laser photorefractive keratectomy (PRK)) patients were treated with Diclofenac Sodium Ophthalmic and/or vehicle placebo. The efficacy of Diclofenac Sodium Ophthalmic given before and shortly after surgery was favored over vehicle placebo during the 6-hour period following surgery for the clinical assessments of pain and photophobia. Patients were permitted to use a hydrogel soft contact lens with Diclofenac Sodium Ophthalmic for up to three days after PRK.

Diclofenac Sodium Ophthalmic is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction and for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery.

Diclofenac Sodium Ophthalmic is contraindicated in patients who are hypersensitive to any component of the medication.

The refractive stability of patients undergoing corneal refractive procedures and treated with Diclofenac Sodium Ophthalmic has not been established. Patients should be monitored for a year following use in this setting.

With some nonsteroidal anti-inflammatory drugs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory agents. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.

All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.

Use of topical NSAIDs may result in keratitis. In some susceptible patients continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal infiltrates, corneal erosion, corneal ulceration, and corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.

Postmarketing experience with topical NSAIDs suggests that patients experiencing complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface disease (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period-of-time may be at increased risk for corneal adverse events, which may become sight threatening. Topical NSAIDs should be used with caution in these patients.

Postmarketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post surgery may increase patient risk for occurrence and severity of corneal adverse events.

It is recommended that Diclofenac Sodium Ophthalmic, like other NSAIDs, be used with caution in patients with known bleeding tendencies or who are receiving other medications, which may prolong bleeding time.

Results from clinical studies indicate that Diclofenac Sodium Ophthalmic has no significant effect upon ocular pressure. However, elevations in intraocular pressure may occur following cataract surgery.

Except for the use of a bandage hydrogel soft contact lens during the first 3 days following refractive surgery, Diclofenac Sodium Ophthalmic should not be used by patients currently wearing soft contact lenses due to adverse events that have occurred in other circumstances.

Long-term carcinogenicity studies in rats given Diclofenac Sodium Ophthalmic in oral doses up to 2 mg/kg/day (approximately 500 times the human topical ophthalmic dose) revealed no significant increases in tumor incidence. A 2-year carcinogenicity study conducted in mice employing oral Diclofenac Sodium Ophthalmic up to 2 mg/kg/day did not reveal any oncogenic potential. Diclofenac Sodium Ophthalmic did not show mutagenic potential in various mutagenicity studies including the Ames test. Diclofenac Sodium Ophthalmic administered to male and female rats at 4 mg/kg/day (approximately 1000 times the human topical ophthalmic dose) did not affect fertility.

No overall differences in safety or effectiveness have been observed between elderly and younger adult patients.

Pregnancy Category C. Reproduction studies performed in mice at oral doses up to 5,000 times (20 mg/kg/day) and in rats and rabbits at oral doses up to 2,500 times (10 mg/kg/day) the human topical dose have revealed no evidence of teratogenicity due to Diclofenac Sodium Ophthalmic despite the induction of maternal toxicity and fetal toxicity. In rats, maternally toxic doses were associated with dystocia, prolonged gestation, reduced fetal weights and growth, and reduced fetal survival. Diclofenac Sodium Ophthalmic has been shown to cross the placental barrier in mice and rats.

There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Because of the known effects of prostaglandin biosynthesis-inhibiting drugs on the fetal cardiovascular system (closure of ductus arteriosus), the use of Diclofenac Sodium Ophthalmic during late pregnancy should be avoided.

Safety and effectiveness in pediatric patients have not been established.

Clinical Practice:   The following events have been identified during postmarketing use of topical Diclofenac Sodium Ophthalmic Solution, 0.1% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical Diclofenac Sodium Ophthalmic Solution, 0.1%, or a combination of these factors, include corneal erosion, corneal infiltrates, corneal perforation, corneal thinning, corneal ulceration, epithelial breakdown, and superficial punctate keratitis, (see PRECAUTIONS, General).

Ocular:  Transient burning and stinging were reported in approximately 15% of patients across studies with the use of Diclofenac Sodium Ophthalmic. In cataract surgery studies, keratitis was reported in up to 28% of patients receiving Diclofenac Sodium Ophthalmic, although in many of these cases keratitis was initially noted prior to the initiation of treatment. Elevated intraocular pressure following cataract surgery was reported in approximately 15% of patients undergoing cataract surgery. Lacrimation complaints were reported in approximately 30% of case studies undergoing incisional refractive surgery.

The following adverse reactions were reported in approximately 5% or less of the patients: abnormal vision, acute elevated IOP, blurred vision, conjunctivitis, corneal deposits, corneal edema, corneal opacity, corneal lesions, discharge, eyelid swelling, injection, iritis, irritation, itching, lacrimation disorder and ocular allergy.

Systemic: The following adverse reactions were reported in 3% or less of the patients: abdominal pain, asthenia, chills, dizziness, facial edema, fever, headache, insomnia, nausea, pain, rhinitis, viral infection, and vomiting.

Overdosage will not ordinarily cause acute problems. If Diclofenac Sodium Ophthalmic is accidentally ingested, fluids should be taken to dilute the medication.

Cataract Surgery: One drop of Diclofenac Sodium Ophthalmic should be applied to the affected eye, 4 times daily beginning 24 hours after cataract surgery and continuing throughout the first 2 weeks of the post operative period.

Corneal Refractive Surgery: One or two drops of Diclofenac Sodium Ophthalmic should be applied to the operative eye within the hour prior to corneal refractive surgery. Within 15 minutes after surgery, one or two drops should be applied to the operative eye and continued 4 times daily for up to 3 days.

Diclofenac Sodium Ophthalmic 0.1% (1 mg/mL) Sterile Solution is supplied in a low-density polyethylene (LDPE) white bottle with a LDPE Dropper Tip. The 2.5 mL fill and the 5 mL fill are supplied in a 7.5 mL size bottle.

2.5 mL NDC 21695-710-25   5 mL NDC 21695-710-05

Store at 20°C to 25°C (68° to 77°F). Protect from light.

Dispense in original, unopened container only.

Rx Only

Revised September 2007

Bausch & Lomb Incorporated Tampa, Florida 33637©Bausch & Lomb Incorporated

Repackaged by:

Rebel Distributors Corp

Thousand Oaks, CA 91320

NDC 21695-710-25

Bausch & Lomb

Diclofenac Sodium Ophthalmic Solution, 0.1% (Sterile)

Rx only

[icon- eye] [icon- 0.1%] [icon- solution] [icon- 5 mL]

Manufacturer

Rebel Distributors Corp

Active Ingredients

Source

Drugs and Medications [283 Associated Drugs and Medications listed on BioPortfolio]

Diclofenac sodium [blenheim pharmacal, inc.]

Diclofenac Sodium Delayed-release Tablets USP, 25 mg, 50 mg and 75 mg

Diclofenac sodium [proficient rx lp]

Diclofenac Sodium Delayed-Release Tablets, USP 25 mg, 50 mg and 75 mg

Diclofenac sodium [preferred pharmaceuticals, inc.]

Diclofenac Sodium Extended-Release Tablets, USP Tablets of 100 mg Rx only Prescribing Information

Dermasilkrx diclopak [patchwerx labs, inc.]

NA

Dermasilkrx diclopak [patchwerx labs, inc.]

NA

Clinical Trials [1828 Associated Clinical Trials listed on BioPortfolio]

Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium

The purpose of this study is to assess the pharmacokinetic parameters of intravenous diclofenac sodium (DIC075V) 18.75 mg and 37.5 mg following single- and multiple-dose administration, as...

Comparison of the Bioavailability of Diclofenac in a Diclofenac+Capsaicin Combination Gel to a Reference Product of Diclofenac Gel in Healthy Volunteers

The main objective of this study is to assess the relative systemic bioavailability of diclofenacin the presence and absence of capsaicin by comparing the systemic bioavailability of diclo...

Wound Infiltration With Sodium Diclofenac vs Bupivacaine for Postoperative Pain Following Appendectomy

The infiltration of the surgical wound is an effective strategy for postoperative analgesia. Nonsteroidal antiinflammatories are useful in this way. Objective: To compare the analgesic ef...

Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers

To evaluate if a single dose of safinamide 200 mg has an effect on the pharmacokinetics of diclofenamic acid, concomitantly administered as a single 50 mg diclofenac sodium dose, with resp...

Evaluation of Bioavailability of Diclofenac Dermal Products

The study will utilize already FDA-approved marketed diclofenac products in healthy adults to generate data for establishing rate of drug delivery comparisons between diclofenac epolamine ...

PubMed Articles [1794 Associated PubMed Articles listed on BioPortfolio]

Characterisation and optimisation of diclofenac sodium orodispersible thin film formulation.

Oral Thin Film (OTF) is a newly emerging drug delivery system which has many benefits for patients. Although there has been some formulation of OTF products, these have mainly been as confectionary or...

Development an LC-MS/MS Method for the Quantification of Diclofenac Sodium in Dairy Cow Plasma and its Application in Pharmacokinetics Studies.

An LC-MS/MS method with internal standard tolfenamic acid for determining diclofenac sodium (DCF) in dairy cow plasma was developed and validated. Samples were processed with protein precipitation by ...

Comparison of the Effects of Piroxicam and Diclofenac Sodium as Treatments for Primary Dysmenorrhea.

BACKGROUND NSAIDs are the most common agents used in dysmenorrhea treatment. They reduce menstrual pain by reducing uterine pressure and PGF2alpha levels in the menstrual fluid. The aim of this study ...

Ex vivo transdermal absorption of a liposome formulation of diclofenac.

Topical formulations of non-steroidal anti-inflammatory drugs are often used to provide effective local drug concentration while limiting systemic exposure and associated adverse events. Formulation c...

Simultaneous penetration monitoring of oil component and active drug from fluorinated nanoemulsions.

In the field of dermal drug delivery, determining the penetration depth of actives is a standard procedure for the development of novel formulations. Regarding the vehicle components, respective penet...

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Drugs and Medication Quicklinks


Searches Linking to this Drug Record